Why the study?
Does continuing ACE-I or ARB therapy reduce all-cause mortality compared to discontinuation in persons with low estimated glomerular filtration rate?
Does continuing ACE-I or ARB therapy reduce all-cause mortality compared to discontinuation in persons with low estimated glomerular filtration rate?
Continuing ACE-I or ARB therapy in patients with declining kidney function may provide cardiovascular benefits without increasing the risk of end-stage kidney disease.
May support continuation despite falling eGFR; leaves open randomized confirmation of net benefit.
The findings suggest that continuing ACE-I or ARB therapy in patients with declining kidney function may be associated with cardiovascular benefit without excessive harm of ESKD.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: